# Phase 3 fibrosis trials recruiting: 26 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials in phase 3 for fibrosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 fibrosis trials: 26 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/fibrosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 26
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 9, 2026 | NCT07868419 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | Trevi Therapeutics | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868419) |
| September 11, 2026 | NCT07816185 | A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) | Pulmovant, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816185) |
| July 22, 2026 | NCT07719023 | A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 263 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719023) |
| July 15, 2026 | NCT07704892 | A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to... | GlaxoSmithKline | Phase 3 | Recruiting | Metabolic Dysfunction-associated Steatohepatitis | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704892) |
| July 14, 2026 | NCT07701993 | A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With... | GlaxoSmithKline | Phase 3 | Recruiting | Metabolic Dysfunction-associated Steatohepatitis | 1,740 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701993) |
| July 7, 2026 | NCT07687459 | Study Evaluation Rentosertib (INS018\_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) | InSilico Medicine Hong Kong Limited | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687459) |
| June 26, 2026 | NCT07671911 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets | Trevi Therapeutics | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671911) |
| June 25, 2026 | NCT07668778 | Evaluation of a Modified Bowel Preparation Regimen in Cirrhotic Patients Undergoing Colonoscopy | Hospital do Divino Espírito Santo de Ponta Delgada | Phase 3 | Not yet recruiting | Cirrhosis, Bowel Preparation | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668778) |
| April 14, 2026 | NCT07529262 | Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial | Curtin University | Phase 3 | Not yet recruiting | Liver Cirrhosis | 890 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529262) |
| April 9, 2026 | NCT07520110 | Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis | University of Massachusetts, Worcester | Phase 3 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07520110) |
| March 11, 2026 | NCT07464912 | A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis... | Beijing Tide Pharmaceutical Co., Ltd | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464912) |
| March 2, 2026 | NCT07441408 | Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Pulmonary Fibrosis | 2,380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441408) |
| February 9, 2026 | NCT07395141 | Albumin in Acute Variceal Bleeding | King George's Medical University | Phase 3 | Not yet recruiting | Acute Variceal Bleeding, Cirrhosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07395141) |
| December 23, 2025 | NCT07299695 | Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis | Sponsor not shown (see the record) | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299695) |
| December 16, 2025 | NCT07284602 | Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis... | PureTech | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284602) |
| July 24, 2025 | NCT07082842 | Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | Sunshine Lake Pharma Co., Ltd. | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 472 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082842) |
| May 30, 2025 | NCT06996951 | Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | Indiana University | Phase 3 | Recruiting | Cystic Fibrosis (CF), Chronic Rhinosinusitis (CRS) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06996951) |
| April 23, 2025 | NCT06941415 | Bumetanide vs. Furosemide in Cirrhosis | Sponsor not shown (see the record) | Phase 3 | Recruiting | Cirrhosis | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06941415) |
| January 6, 2025 | NCT06758739 | Comparison of Curcumin and Intralesional Steroids in Oral Submucous Fibrosis | Services Institute of Medical Sciences, Pakistan | Phase 3 | Not yet recruiting | Oral Submucous Fibrosis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06758739) |
| June 14, 2024 | NCT06461208 | A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis | King's College London | Phase 3 | Recruiting | Liver Cirrhosis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06461208) |
| May 17, 2024 | NCT06419374 | A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Hoffmann-La Roche | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06419374) |
| March 19, 2024 | NCT06318169 | A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Hoffmann-La Roche | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis | 1,350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06318169) |
| March 15, 2023 | NCT05769868 | Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments | Consorcio Centro de Investigación Biomédica en Red (CIBER) | Phase 3 | Recruiting | Cirrhosis, Diabetes Mellitus, Oncologic Disorders | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05769868) |
| January 21, 2022 | NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Can-Fite BioPharma | Phase 3 | Recruiting | Hepatocellular Carcinoma, Cirrhosis | 471 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05201404) |
| October 12, 2021 | NCT05075161 | Pirfenidone to Prevent Fibrosis in Ards. | Università Vita-Salute San Raffaele | Phase 3 | Recruiting | Acute Respiratory Distress Syndrome (ARDS) | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05075161) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| Trevi Therapeutics | 2 |
| Indiana University | 1 |
| King George's Medical University | 1 |
| Pulmovant, Inc. | 1 |
| University of Massachusetts, Worcester | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Università Vita-Salute San Raffaele | 1 |
| Norfolk and Norwich University Hospitals NHS Foundation Trust | 1 |
| PureTech | 1 |
| King's College London | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| Consorcio Centro de Investigación Biomédica en Red (CIBER) | 1 |
| [Sunshine Lake Pharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-lake-pharma-co-ltd) | 1 |
| [Can-Fite BioPharma](https://specstream.ai/data/clinical-trials/company/can-fite-biopharma) | 1 |
| [Shanghai Ark Biopharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-ark-biopharmaceutical-co-ltd) | 1 |
| Beijing Tide Pharmaceutical Co., Ltd | 1 |
| Curtin University | 1 |
| Services Institute of Medical Sciences, Pakistan | 1 |
| Hospital do Divino Espírito Santo de Ponta Delgada | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| China | 5 |
| United Kingdom | 5 |
| India | 4 |
| Canada | 4 |
| Israel | 4 |
| Italy | 4 |
| Japan | 4 |
| Spain | 4 |
| Argentina | 3 |
| Australia | 3 |
| Belgium | 3 |
| France | 3 |
| Germany | 3 |
| Mexico | 3 |
| Netherlands | 3 |
| South Korea | 3 |
| Taiwan | 3 |
| Bulgaria | 3 |
| Poland | 3 |
| Brazil | 2 |
| Greece | 2 |
| Portugal | 2 |
| Georgia | 2 |
| Hong Kong | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Motorcycle manufacturers in the United States](https://specstream.ai/data/businesses/motorcycle-manufacturers/united-states)
- [Stucco contractors in the United States](https://specstream.ai/data/businesses/stucco-contractors/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
- [Medical schools in the United States](https://specstream.ai/data/businesses/medical-schools/united-states)
- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
